Protocol for Project FACT: a randomised controlled trial on the effect of a walking program and vitamin B supplementation on the rate of cognitive decline and psychosocial wellbeing in older adults with mild cognitive impairment [ISRCTN19227688]

1471-2318-5-18 1471-2318 Study protocol Protocol for Project FACT: a randomised controlled trial on the effect of a walking program and vitamin B supplementation on the rate of cognitive decline and psychosocial wellbeing in older adults with mild cognitive impairment [ISRCTN19227688] van Uffelen GZ Jannique j.vanuffelen@vumc.nl Hopman-Rock Marijke m.hopman@pg.tno.nl Chin A Paw JM Marijke m.chinapaw@vumc.nl van Mechelen Willem w.vanmechelen@vumc.nl

Body@Work, Research Center Physical Activity, Work and Health, TNO-VU University Medical Center, Amsterdam, The Netherlands

Department of Public and Occupational Health, EMGO Institute/VU University Medical Center, Amsterdam, The Netherlands

Dep. of Physical Activity and Health, TNO Quality of Life, Leiden, The Netherlands

BMC Geriatrics 1471-2318 2005 5 1 18 http://www.biomedcentral.com/1471-2318/5/18 16375760 10.1186/1471-2318-5-18 05 10 2005 23 12 2005 23 12 2005 2005 van Uffelen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

the prevalence of individuals with cognitive decline is increasing since the number of elderly adults is growing considerably. The literature provides promising results on the beneficial effect of exercise and vitamin supplementation on cognitive function both in cognitively healthy as well as in the demented elderly.

Methods/Design

the design is a two-by-two factorial randomised controlled trial. The study population consists of independently living elderly, between 70 and 80 years old, with mild cognitive impairment (MCI). In the RCT the effect of two interventions, a walking program and vitamin supplementation, is examined. The walking program (WP) is a group-based program aimed at improving cardiovascular endurance; frequency two lessons a week; lesson duration one hour; program duration one year. Non-walking groups receive a placebo activity program (PAP) (i.e. low intensive non-aerobic group exercises, like stretching) with the same frequency, lesson and program duration. Vitamin supplementation consists of a single daily vitamin supplement containing 50 mg B6, 5 mg folic acid and 0,4 mg B12 for one year. Subjects not receiving vitamin supplements are daily taking an identically looking placebo pill, also for a year. Participants are randomised to four groups 1) WP and vitamin supplements; 2) WP and placebo supplements; 3) PAP and vitamin supplements; 4) PAP and placebo supplements. Primary outcome measures are measures of cognitive function. Secondary outcomes include psychosocial wellbeing, physical activity, cardiovascular endurance and blood vitamin levels.

Discussion

no large intervention study has been conducted yet on the effect of physical activity and vitamin supplementation in a population-based sample of adults with MCI. The objective of the present article is to describe the design of a randomised controlled trial examining the effect of a walking program and vitamin B supplementation on the rate of cognitive decline in older adults with MCI.

Background

Because cognitive function decreases with age and the number of elderly is increasing worldwide, the number of older adults with cognitive dysfunction is also increasing. Since no cure for dementia is available yet, this process will put a considerable burden on the healthcare system and on society in general. Therefore, for both individuals and society it is necessary to develop strategies for maintaining physical, mental and cognitive wellbeing of the aging population.

In this manuscript the design is described of a randomised controlled trial on the effect of a moderate intensive walking program and vitamin B-supplementation in an older population with mild cognitive impairment (MCI) recruited from the general population.

Mild cognitive impairment

MCI refers to a stage in which persons experience memory loss to a greater extent than one would expect for age, but do not yet meet currently accepted criteria for clinically probable dementia or Alzheimer Disease (AD) 1. Prevalence of MCI in adults with a mean age of 75 years is three to four percent 23. Compared to elderly with normal cognitive function, adults with MCI have an increased risk to develop dementia or AD 145. Progression rates to dementia and AD for adults with MCI vary from 6 % to 25 % per year, depending on the criteria for MCI 6. The rate of progression to AD in adults with MCI according to the criteria of Petersen et al. is 12%, compared with a rate of 1–2% per year in control subjects 4.

As the stage of MCI may be the optimum stage at which to intervene with preventive therapies 78, new treatments to prevent development of AD are targeting elderly with MCI 7.

Physical activity

The hypothesis of physical activity positively influencing cognition is supported by observational studies that found higher levels of physical activity were associated with a reduced risk of cognitive decline and dementia in healthy elderly 910111213.

Positive effects of exercise programs on cognitive function have been found also in various trials among cognitively healthy elderly 14151617. Programs lasted from two months 14 to one year 16, frequency and intensity differed per program. Improvements in memory 14, immediate recall 1617 and tasks requiring executive control processes 15 have been reported.

Also a number of reviews and a meta-analysis have been conducted on the effects of physical exercise on cognition in healthy elderly 181920. Exercise seems to have a positive effect on cognitive functioning, but findings in the individual studies are contradictory and the effect size can be considered small. However, two recently published meta-analyses reported moderate effect size values, around 0.5, from group based aerobic fitness training on cognitive performance in healthy elderly 21 and from various types of exercise programs in elderly with dementia 22.

Besides an effect on cognitive function, Biddle and Faulkner 23 concluded in their review that clear beneficial effects from physical activity are evident for psychosocial wellbeing in older adults.

Possible pathways for the effect of physical activity on cognitive function are increased blood flow to the brain, improved vascularisation, improved neurogenesis, increased neurotransmitter availability and better neural efficiency2425.

Vitamin B supplementation

Cognitive function may benefit as well from supplementation with folic acid, vitamin B12 and vitamin B6 (FA/B12/B6 respectively). Metabolic FA/B12/B6 deficiencies are relatively common in older adults 2627, even in the presence of normal serum vitamin levels 28. Low levels of FA/B12/B6 seem to be associated with poorer cognitive function 293031. Besides a reverse effect on cognitive function, FA/B12/B6 deficiencies result in elevated levels of the amino acid homocysteine 32, as these vitamins are linked to the metabolism of homocysteine.

An elevated homocysteine level has been found to be a strong independent risk factor for the development of dementia and AD as well 33. Negative associations have been found between increased homocysteine levels and global cognitive performance 343536, memory 3738, psychomotor speed 3839 and spatial copying skills 29, even in the generally normal accepted range of homocysteine (25^th–75^thpercentile (7.6–11.3 μmol/L)) 38. Above a threshold of approximately 14 μmol/L significantly lower cognitive performances were observed as well 394041.

Supplementation with vitamin B reduces the homocysteine level 4243. Supplementation with folic acid after standardisation for pre-treatment blood concentrations of homocysteine and folic acid resulted in an approximate decrease of homocysteine level of 25 percent. Vitamin B12 produced an additional 7 percent reduction 44.

Few experimental studies have been conducted on the effect of B-vitamin supplementation in enhancing cognitive performance in older adults. Bryan and Calvaresi (2002) 45 found a significant effect on memory performance after 35 days of (FA/B12/B6) supplementation in healthy middle aged and older women. Fioravanti et al. 46 concluded in a double blind controlled trial that 15 mg folic acid daily for 60 days given to older adults with global impairment in all components of memory functioning (i.e. a more seriously decline than MCI), appeared to improve their memory. Vitamin B12 injections of different doses improved memory in elderly with B12 deficiency and without cognitive impairment in a single blind controlled trial 47. Finally, cognitive performance in elderly with elevated plasma homocysteine and a diagnosis of mild to moderate dementia improved after combined supplementation of 5 mg folic acid and 1 mg vitamin B12 daily for two months 48. Unfortunately most of these trials included few subjects and, therefore, results have to be interpreted with care.

Calvaresi and Bryan (2001) hypothesised that FA/B12/B6 may affect cognitive performance via two interrelated ways: a direct and possibly acute influence via hypomethylation and a longer term influence on homocysteine levels resulting in structural vascular changes in the brain 49.

No clinical trials are yet available that have examined the effect of physical activity and vitamin supplementation in a population based sample of adults with MCI. Therefore, the main objective of project FACT (Folate physical Activity Cognition Trial) is to examine the effect of a walking program and vitamin B supplementation on the rate of cognitive decline in adults aged 70 to 80 years with mild cognitive impairment in a randomised controlled trial. Also effects of both interventions on psychosocial wellbeing, habitual physical activity and cardiovascular endurance will be examined.

Methods/Design

Study design

The study is designed as a randomised, placebo controlled intervention trial, based on a two-by-two factorial design. The design is presented in figure 1. It is assumed that the effect of both interventions is independent. The study protocol was approved by the VU University Medical Center medical ethics committee.

Figure 1

Design of the RCT (WP = walking program, PAP = placebo activity program)

Design of the RCT (WP = walking program, PAP = placebo activity program).

Setting

This study is carried out in Alkmaar, a medium sized city in The Netherlands, with approximately 100,000 inhabitants.

Study population

This study is targeted at a population based sample meeting the criteria for mild cognitive impairment: i.e. memory complaint, memory impairment, normal general cognitive function, normal activities of daily living and not demented 4. In the recruitment procedure the criteria for MCI are checked in both a questionnaire and a telephone interview. Other inclusion criteria for participating in the trial are checked for only in the questionnaire (table 1).

Table 1

Inclusion criteria

Criteria for MCI (1–4) and other inclusion criteria for the RCT (5–11)

1. self reported memory complaints (answer yes to question 'do you have memory complaints', or at least twice sometimes at cognition scale of Strawbridge)

2. no report of disability in activities of daily living on GARS-scale, except on the item 'taking care of feet and toe nails'

3. objective memory impairment; 10 wlt delayed recall ≤5 + percentage savings ≤ 100

4. normal general cognitive functioning/absence of dementia; TICS ≥ 19

5. being able to moderate intensive physical activity without making use of walking devices, e.g. rollator, of walking frame

6. not using vitamin supplements/vitamin injections/drinks with dose of vitamin B6, B11 or B12 comparable to vitamin supplement given in intervention

7. not suffering from epilepsy, multiple sclerosis, Parkinson's disease, kidney disorder requiring haemodialysis, psychiatric impairment

8. not suffering from depression as measured by the Geriatric Depression Scale (cut off ≤ 5)

9. not using medication for rheumatoid arthritis or psoriasis interfering with vitamin supplement

10. no alcohol abuse (men < 21 consumptions a week, women < 15 consumptions a week)

11. not currently living in or on a waiting list for a nursing home

Questionnaire

To recruit participants a questionnaire is sent to all independently living elderly in Alkmaar, with an age between 70 and 80 years old. Their addresses are provided by the register of population of the municipality of Alkmaar. Primary aim of the questionnaire is to check two criteria for MCI, memory complaints and normal activities of daily living. Memory complaints are assessed by the question 'do you have memory complaints' and the cognition scale of Strawbridge 50. Activities of daily living (ADL) are assessed using the Groningen Activity Restriction Scale (GARS) 51. Secondary aims are to collect demographic variables and to check the other inclusion criteria for trial participation. Together with filling in the questionnaire, participants are requested to give informed consent.

Telephone interview

Respondents fulfilling the inclusion criteria are being phoned for a telephone interview for cognitive status. In this telephone interview a brief measure of general cognitive function (TICS) 52 and a modified version of the ten word learning test 53 are administered. Adults with a score of 20 or more on the TICS, corresponding to normal cognitive function, and with a performance on the delayed recall score on the ten word learning test of less than five are considered as having mild cognitive impairment. A delayed recall score of five or less corresponds with one standard deviation below normal performance 54. Participants fulfilling these criteria receive an invitation letter for a baseline measurement during a personal interview.

Sample size

The aim is to enrol 170 participants. A power analysis has been executed on the auditory verbal learning test. To be able to detect a difference of 5 points on direct recall (see 2.9.1) 34 participants per group are required and thus 136 participants in total. These numbers are based on a power of 80% and a significance level of 0.05. We expect a drop-out rate of 25 percent, based on experiences with comparable research. Therefore, 170 participants will be recruited.

Randomization

To ensure an equal distribution of physically inactive and active subjects in each group, participants are classified as active or inactive on the basis of their activity level as measured using the LASA physical activity questionnaire 55. Adults with an activity level exceeding the median level of the whole group are classified as active and adults below this level are classified as inactive. Active and inactive subjects are allocated separately and randomly to one of the four intervention groups using the option 'random sample of cases' in the statistical computer program SPSS.

Blinding

The study is conducted double blind. The key of coding for FA/B12/B6 supplementation is only known to the manufacturer of the supplements, who will decode the key after data-analysis. All outcome measures on cognition and wellbeing are assessed by independent examiners unaware of group allocation.

Co-interventions and compliance

During the intervention period co-interventions are discouraged by asking adults not to start an exercise program or vitamin supplementation while being a participant. Both vitamin supplementation and physical activity level will be asked for at baseline and after 6 and 12 months.

Compliance with the walking program is assessed as the percentage of attended lessons. Compliance with the vitamin supplementation is verified by pill counts and determining blood vitamin levels.

Intervention

Walking program and placebo activity program

Walking program (WP)

The walking program is based on 'Sportive Walking', an existing aerobic exercise program 56. Each lesson consists of a warming-up, moderate intensity walking exercises and a cooling-down. Lessons for project FACT are developed by two certified walking instructors and recorded in a manual. The duration and intensity of the WP are increased gradually during the program by increasing the total walking time and distance. The WP is developed in such a way that all subjects can perform the walking exercises at their own level, but still walk in a group. This is for example established by using walking routes with the same beginning and end.

Lessons are being given outdoors in municipal parks in Alkmaar. Only when it is slippery due to snow or freezing rain the lessons will be cancelled.

Placebo activity program (PAP)

The PAP is developed by four experienced exercise instructors. The program consists of an introduction, low intensity non-aerobic group exercises such as light range of motion movements and stretching, and a closing. Lessons are divided into five themes: relaxation, activities of daily living, balance, flexibility, posture, and a combination of all. For each theme three lessons are developed and the entire series of 18 lessons is repeated during the intervention period. The program takes place in a community center.

Both programs are group-based and last one year, the frequency is twice a week and lesson duration is 60 minutes. The intensity is checked by heart rate monitors (Polar, Vantage NV) and Borg scales in a sub sample of the population during one lesson at baseline and after twelve months and during two lessons at six months follow up.

To provide an intervention class in or near the subjects' own neighbourhood, eight classes for the walking program and eight classes for the placebo activity program are started in four districts. These classes are organized especially for the study and only study participants are able to join. All exercise classes are supervised by qualified instructors. In total four trained walking instructors for the walking program and four exercise instructors for the placebo activity program are hired for the study. The number of participants in a group is 19 at the most.

Folic acid/vitamin B12/vitamin B6 supplementation

Subjects in the intervention group are asked to take daily one pill containing 5 mg folic acid, 0.4 mg vitamin B12 and 50 mg B6 during a year. Subjects who do not get FA/B12/B6 supplementation receive an identically looking placebo pill. The pills are packed in blister packs containing seven pills that are labelled for each day of the week.

Measurements

All outcome measures are collected at baseline and after 6 and 12 months. The primary outcome measures are measures of cognitive function. Secondary measures are measures of psychosocial health, habitual physical activity and cardiovascular endurance. Also physical measures are performed. Most cognitive and psychosocial data are gathered during a standardized interview. These face-to-face interviews are conducted in the Medical Center Alkmaar and last a maximum of 90 minutes, including a short break.

Primary outcome measures

Five interviewer administered cognitive outcome measures are chosen to assess different aspects of cognitive functioning. Only the informant questionnaire is self administered.

Mini Mental State Examination (MMSE)

general cognitive function is measured with the MMSE. The MMSE consists of 11 questions concerning orientation, registration, attention and calculation, recall and language. The maximum score is 30 and a score below 24 is considered abnormal for dementia screening 57.

Auditory Verbal Learning Test (AVLT)

a Dutch version of the AVLT is used. This is a measure of memory in which direct and delayed recall are assessed. During the test a list of 15 monosyllabic words is read aloud by the examiner for 5 times. After each trial the subject is asked to repeat the words he or she remembers. After fifteen minutes with other questions, delayed recall is assessed by asking the participant which words he or she still remembers 58. At baseline and after 12 months the same version of the test is administered and after 6 months a parallel version with 15 different words is administered.

Letter fluency test (LFT)

this is a measure of expressive language. If language is intact, the LFT is also a measure of executive functioning. The subject is given a letter and is asked to name words beginning with the particular letter in one minute. In one administration of the test three letters are given. At the 6 and 12 months follow up measurements parallel versions with different letters are administered 59.

Digit symbol substitution test (DSST)

This is a measure of attention, perceptual speed, motor speed, visual scanning and memory. The subject is given a piece of paper with nine symbols corresponding with nine digits. Next on this piece of paper are three rows of digits with empty spaces below them. The subject is asked to fill in as many corresponding symbols as possible in 90 seconds 60.

Abridged Stroop colour word test (SCWT-A)

this is a measure of complex processing. The SCWT-A consist of three tasks; 1) word reading, 8 rows of 5 written colours; 2) colour naming, naming the colours of 8 rows of 5 red, green, blue or yellow coloured rectangles; 3) combination task, the words red, green, blue or yellow have been printed in a different colour of ink, the subject is asked to name the colour of the ink 61.

Informant questionnaire on cognitive decline (IQ-code)

in this questionnaire a significant other of the participant is asked to answer 16 questions about changes in the participant's cognitive function during the last ten years 6263.

Secondary measures

Three interviewer administered questionnaires are used to complete the picture of psychosocial health. Only the geriatric depression scale is self administered.

psychosocial wellbeing

Short Form 12 (SF-12)

The SF-12 is a measure of health status consisting of twelve items measuring eight concepts of both physical and mental health. The physical and mental component summary scales are scored using norm-based methods 64.

Dementia Quality of Life (D-QoL)

The D-QoL is a 29 item measure especially developed for elderly with cognitive decline and dementia. Five domains are measured: self esteem, positive affect/humour, negative affect, feelings of belonging and sense of aesthetics. The response scale is a five point scale with higher score indicating better quality of life 65.

Euro Quality of Life (Euro-QoL)

The Euro-QoL questionnaire is a standardized measure for general health status measuring five dimensions: mobility, self care, usual activities, pain/discomfort and anxiety/depression. The participant is asked to choose from three answer levels for each dimension. By composing a five digit number consisting of the three answer levels on the five dimensions participants can be classified into one of 243 defined health states 66.

Geriatric Depression Scale (GDS)

The GDS is a self administered depression scale for the elderly. The short version is used in which participants are asked to report how they felt the last week by answering 15 yes/no questions. The maximum score is 15 and a score over five points is suggestive of depression 67.

physical activity and cardiovascular endurance

Physical activity level

During the face-to-face interview the LASA physical activity questionnaire 55 is administered to determine the physical activity level of the participants. Participants are interviewed about their physical activities during the last two weeks by asking questions about the frequency and duration of different activities (e.g. housekeeping, sports activities, cycling, gardening). These answers are converted to an overall physical activity score expressed in minutes of physical activity per day.

Accelerometer

A random sample of subjects of each of the four intervention groups is asked to wear an accelerometer (ActiGraph, activity monitor) for three days. Data will be used to compare the level of activity in participants in the walking program and in the placebo activity group.

Cardiovascular endurance

this is assessed in a sports hall using the walking test of the Groningen Fitness test for the elderly 68. This is a sub-maximal test for aerobic endurance in which adults walk distances of 16.6 meters between pylons in a large rectangle of 16.6 by 8.3 meters. For every walked distance a score of one point is given. To increase their score, adults have to be within a three meter distance of the next pylon before a signal sounds. A double signal sounds when walking speed is increased. Walking speed is increased every three minutes with one kilometre starting with a walking speed of four kilometres per hour to a maximum walking speed of seven kilometres per hour. If they fail twice to reach the next pylon in time, the test is finished for that particular participant. The maximum score of 66 points corresponds to a total walking distance of 1.1 kilometres.

Physical measures

Anthropometric measurements

During the break in the face-to-face interview body height and body weight are measured for calculating body mass index (kg/m²).

Blood pressure

Blood pressure is measured electronically (Omron M5-1) after five minutes of rest during the face-to-face interview. Participants with a diastolic blood pressure exceeding 95 and a systolic blood pressure exceeding 160 are offered to have their blood pressure measured again by a geriatrician. If hypertension is diagnosed, the participant will be treated.

Blood vitamin levels

non-fasting blood samples are taken at the laboratory of the Medical Center Alkmaar to determine blood vitamin levels.

Plasma concentrations of homocysteine, serum folate levels and vitamin B12 levels in serum are determined by a competitive immunoassay using direct chemiluminescent technology. (ADVIA CENTAUR, Bayer Corporation, Tarrytown, USA).

For determination of red cell folate hemolysates are prepared out of EDTA plasma and ascorbic acid. Folate in erythrocytes is determined in the hemolysate by a competitive immunoassay using direct chemiluminescent technology (ADVIA CENTAUR, Bayer Corporation, Tarrytown, USA). According to the manufactures instructions folate in erythrocytes is calculated using the following algorithm: folate in hemolysate × 21 minus folate in serum × ((100 – hematocrit)/(hematocrit * 100)).

Vitamin B6 in plasma is determined by high performance liquid chromatography with fluorescence detection using Chrompack Lichrosorb RP-18 columns (Varian Inc., Palo Alto, USA) and the Jasco HPLC system (Jasco Benelux, Maarssen, The Netherlands).

Statistical analyses

Analyses will focus upon estimating the effect of both interventions on four domains: 1) cognitive functioning; 2) psychosocial wellbeing; 3) habitual physical activity and cardiovascular endurance; 4) blood vitamin levels and homocysteine. The effect of physical activity and FA/B12/B6 supplementation will be examined independently from each other as we do not expect an interaction between these interventions.

Before analyses are performed there will be a check-up on the comparability at baseline of the intervention groups. If necessary, analyses will be adjusted for baseline differences. Subsequently, the data set will be analysed according to the intention to treat and according to the intention per protocol principle.

The difference between the walking program and the placebo activity program, and between the verum and placebo supplements will be assessed using linear regression. The dependent variables will be values after 6 and 12 months in the four before mentioned domains. Both interventions will be independent variables. Besides, regression analyses will be adjusted for baseline values and possibly confounding covariates such as gender and age. Also effect modification by sex will be investigated using interaction terms.

Discussion

The literature provides promising results on the beneficial effect of exercise and folic acid/vitamin B12/vitamin B6 supplementation on cognitive function and wellbeing both in cognitive healthy as well as in the demented elderly. However, to our knowledge, no large intervention study has been conducted yet on the effect of these interventions on cognitive decline in subjects with MCI. In the present study, the effects on cognitive function and psychosocial health will be examined in a population sample of community dwelling elderly adults aged 70 to 80 years. A factorial design is used and it is assumed that the interventions have an independent effect. We hypothesize that both exercise and FA/B12/B6 supplementation beneficially influence cognitive function and psychosocial health in this particular group of elderly.

The results of this trial will provide clinicians in the field of aging with more knowledge about treatment of older persons with cognitive decline. If proven effective, exercise and vitamin supplementation are an additional intervention method for this target group.

Implementation of the walking program in the Netherlands is relatively easy, since infrastructure for group based exercise programs for the elderly already exists.

Vitamin supplementation is easy to implement as well. The most difficult aspect might be long term compliance in case of severe cognitive decline. However, compliance can be sustained by providing methods to remember taking the vitamin supplements.

An additional important advantage of both interventions is that involvement of the clinician is limited to prescribing exercise and vitamin supplementation and possibly to evaluate compliance at future medical check-ups.

Abbreviations

AVLT: auditory verbal learning test

D-QoL: dementia quality of life

DSST: digit symbol substitution test

Euro-QoL: European quality of life

FA/B12/B6: folic acid, vitamin B12, vitamin B6

GARS: Groningen activity restriction scale

GDS: geriatric depression scale

IQ-code: informant questionnaire for cognitive function

LFT: letter fluency test

MCI: mild cognitive impairment

MMSE: mini mental state examination

PAP: placebo activity program

SCWT-A: stroop color word test abridged

SF-12: short form 12

TICS: telephone interview for cognitive status

WP: walking program

Competing interests

The author(s) declare that they have no competing interests.

Author's contributions

MC was involved in developing the basic idea for the study. JvU, MH, MC and WvM were involved in further developing the idea and the protocol for carrying out the study. JvU is responsible for the data collection and she drafted the manuscript. All authors contributed to the final manuscript by reading and correcting draft versions.

Acknowledgements

None.

Current concepts in mild cognitive impairment Petersen RC Doody R Kurz A Mohs RC Morris JC Rabins PV Ritchie K Rossor M Thal L Winblad B Arch Neurol 2001 58 1985 1992 10.1001/archneur.58.12.1985 11735772 Mild cognitive impairment, amnestic type - An epidemiologic study Ganguli M Dodge HH Shen CY DeKosky ST Neurology 2004 63 115 121 15249620 VITA: subtypes of mild cognitive impairment in a community-based cohort at the age of 75 years Jungwirth S Weissgram S Zehetmayer S Tragl KH Fischer P International Journal of Geriatric Psychiatry 2005 20 452 458 10.1002/gps.1311 15852463 Mild cognitive impairment: clinical characterization and outcome Petersen RC Smith GE Waring SC Ivnik RJ Tangalos EG Kokmen E Arch Neurol 1999 56 303 308 10.1001/archneur.56.3.303 10190820 Mild cognitive impairment: conceptual basis and current nosological status Ritchie K Touchon J Lancet 2000 355 225 228 10.1016/S0140-6736(99)06155-3 10675135 Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Petersen RC Stevens JC Ganguli M Tangalos EG Cummings JL DeKosky ST Neurology 2001 56 1133 1142 11342677 Mild cognitive impairment Chertkow H Curr Opin Neurol 2002 15 401 407 10.1097/00019052-200208000-00001 12151835 Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment Yesavage JA O'Hara R Kraemer H Noda A Taylor JL Ferris S Gely-Nargeot MC Rosen A Friedman L Sheikh J Derouesne C J Psychiatr Res 2002 36 281 286 10.1016/S0022-3956(02)00020-1 12127595 Physical activity and risk of cognitive impairment and dementia in elderly persons Laurin D Verreault R Lindsay J MacPherson K Rockwood K Arch Neurol 2001 58 498 504 10.1001/archneur.58.3.498 11255456 Physical activity and cognitive decline, the role of the apolipoprotein e4 allele Schuit AJ Feskens EJ Launer LJ Kromhout D Med Sci Sports Exerc 2001 33 772 777 11323547 A prospective study of physical activity and cognitive decline in elderly women: women who walk Yaffe K Barnes D Nevitt M Lui LY Covinsky K Arch Intern Med 2001 161 1703 1708 10.1001/archinte.161.14.1703 11485502 Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study Podewils LJ Guallar E Kuller LH Fried LP Lopez OL Carlson M Lyketsos CG American Journal of Epidemiology 2005 161 639 651 10.1093/aje/kwi092 15781953 Physical activity, including walking, and cognitive function in older women Weuve J Kang JH Manson JE Breteler MMB Ware JH Grodstein F JAMA 2004 292 1454 1461 10.1001/jama.292.12.1454 15383516 Improvement of cognitive function by mental and/or individualized aerobic training in healthy elderly subjects Fabre C Chamari K Mucci P Masse-Biron J Prefaut C Int J Sports Med 2002 23 415 421 10.1055/s-2002-33735 12215960 Ageing, fitness and neurocognitive function Kramer AF Hahn S Cohen NJ Banich MT McAuley E Harrison CR Chason J Vakil E Bardell L Boileau RA Colcombe A Nature 1999 400 418 419 10.1038/22682 10440369 Effects of group exercise on cognitive functioning and mood in older women Williams P Lord SR Aust N Z J Public Health 1997 21 45 52 9141729 Mood, physical working capacity and cognitive performance in the elderly as related to physical activity Hassmen P Koivula N Aging (Milano ) 1997 9 136 142 9177597 Effects of exercise on cognitive processes: a review. Tomporowski PD Ellis NR Psychological bulletin 1986 99 338 346 10.1037/0033-2909.99.3.338 Effects of physical exercise on cognitive functioning in the elderly. van Sickle TD Hersen M Simco ER Melton MA van Hasselt VB Int J Rehab Health 1996 2 67 100 10.1007/BF02213444 The influence of physical fitness and exercise upon cognitive functioning: a meta-analysis. Etnier JL Salazar W Landers DM Petruzello SJ Myungwoo H Nowell P Journal of Sports & Exercise Psychology 1997 19 249 277 Fitness effects on the cognitive function of older adults: a meta-analytic study Colcombe S Kramer AF Psychol Sci 2003 14 125 130 10.1111/1467-9280.t01-1-01430 12661673 The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis Heyn P Abreu BC Ottenbacher KJ Arch Phys Med Rehabil 2004 85 1694 1704 15468033 10.1016/j.apmr.2004.03.019 Psychological and Social Benefits of Physical Activity. Biddle S Faulkner G Active Aging Hong Kong, Lippinicott, Williams & Wilkins Asia Ltd. Chan KM 2002 89 164 Exercise, experience and the aging brain Churchill JD Galvez R Colcombe S Swain RA Kramer AF Greenough WT Neurobiol Aging 2002 23 941 955 10.1016/S0197-4580(02)00028-3 12392797 Brain function and exercise. Current perspectives Etnier JL Landers DM Sports Med 1995 19 81 85 7747005 Vitamin B12 deficiency in the elderly Baik HW Russell RM Annu Rev Nutr 1999 19 357 377 10.1146/annurev.nutr.19.1.357 10448529 Folate intake of the Dutch population according to newly established liquid chromatography data for foods Konings EJ Roomans HH Dorant E Goldbohm RA Saris WH van den Brandt PA Am J Clin Nutr 2001 73 765 776 11273852 Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations Naurath HJ Joosten E Riezler R Stabler SP Allen RH Lindenbaum J Lancet 1995 346 85 89 10.1016/S0140-6736(95)92113-3 7603218 Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study Riggs KM Spiro AIII Tucker K Rush D Am J Clin Nutr 1996 63 306 314 8602585 The influence of serum vitamin B12 and folate status on cognitive functioning in very old age Robins Wahlin TB Wahlin A Winblad B Backman L Biol Psychol 2001 56 247 265 10.1016/S0301-0511(01)00079-5 11399353 Homocysteine versus the vitamins folate, B-6, and B-12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur studies of successful aging Kado DM Karlamangla AS Huang MH Troen A Rowe JW Selhub J Seeman TE American Journal of Medicine 2005 118 161 167 10.1016/j.amjmed.2004.08.019 15694902 Vitamin status and intake as primary determinants of homocysteinemia in an elderly population Selhub J Jacques PF Wilson PW Rush D Rosenberg IH JAMA 1993 270 2693 2698 10.1001/jama.270.22.2693 8133587 Plasma homocysteine as a risk factor for dementia and Alzheimer's disease Seshadri S Beiser A Selhub J Jacques PF Rosenberg IH D'Agostino RB Wilson PW Wolf PA N Engl J Med 2002 346 476 483 10.1056/NEJMoa011613 11844848 Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people Budge MM de Jager C Hogervorst E Smith AD J Am Geriatr Soc 2002 50 2014 2018 10.1046/j.1532-5415.2002.50614.x 12473014 Homocysteine and cognitive function in elderly people Garcia A Zanibbi K Canadian Medical Association Journal 2004 171 897 904 522658 15477631 10.1503/cmaj.1031586 Homocysteine and cognitive performance in healthy elderly subjects Ravaglia G Forti P Maioli F Scali RC Sacchetti L Talerico T Mantovani V Bianchin M Arch Gerontol Geriatr 2004 349 357 10.1016/j.archger.2004.04.045 15207433 Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey Morris MS Jacques PF Rosenberg IH Selhub J Am J Clin Nutr 2001 73 927 933 11333847 Homocysteine and cognitive function in a population-based study of older adults Schafer JH Glass TA Bolla KI Mintz M Jedlicka AE Schwartz BS Journal of the American Geriatrics Society 2005 53 381 388 10.1111/j.1532-5415.2005.53153.x 15743278 Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study Prins ND Den Heijer T Hofman A Koudstaal PJ Jolles J Clarke R Breteler MM Neurology 2002 59 1375 1380 12427887 Homocysteine, white matter hyperintensities, and cognition in healthy elderly people Dufouil C Alperovitch A Ducros V Tzourio C Ann Neurol 2003 53 214 221 10.1002/ana.10440 12557288 Plasma total homocysteine levels and cognitive function in older high functioning adults; MacArthur studies of successful aging Kado DM Selhub J Seeman TE American Geriatric Society, Paper abstracts 2001 S13 The effect of folic acid supplementation on plasma homocysteine in an elderly population Rydlewicz A Simpson JA Taylor RJ Bond CM Golden MH QJM 2002 95 27 35 10.1093/qjmed/95.1.27 11834770 Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation Woo KS Chook P Chan LL Cheung AS Fung WH Qiao M Lolin YI Thomas GN Sanderson JE Metreweli C Celermajer DS Am J Med 2002 112 535 539 10.1016/S0002-9343(02)01075-6 12015244 Lowering blood homocysteine with folic acid based supplements: meta- analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration BMJ 1998 316 894 898 28491 9569395 Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages Bryan J Calvaresi E Hughes D Journal of Nutrition 2002 132 1345 1356 12042457 Low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits. Fioravanti M Ferrario E Massaia M Cappa G Rivolta G Grossi E Buckley AE Arch Gerontol Geriatr 2002 26 1 13 10.1016/S0167-4943(97)00028-9 Cobalamin supplementation improves cognitive and cerebral function in older, cobalamin-deficient persons van Asselt DZ Pasman JW van Lier HJ Vingerhoets DM Poels PJ Kuin Y Blom HJ Hoefnagels WH J Gerontol A Biol Sci Med Sci 2001 56 M775 M779 11723153 Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine Nilsson K Gustafson L Hultberg B Int J Geriatr Psychiatry 2001 16 609 614 10.1002/gps.388 11424170 B vitamins, cognition, and aging: a review Calvaresi E Bryan J J Gerontol B Psychol Sci Soc Sci 2001 56 P327 P339 11682586 Antecedents of frailty over three decades in an older cohort Strawbridge WJ Shema SJ Balfour JL Higby HR Kaplan GA J Gerontol B Psychol Sci Soc Sci 1998 53 S9 16 9469175 The assessment of disability with the Groningen Activity Restriction Scale. Conceptual framework and psychometric properties Kempen GI Miedema I Ormel J Molenaar W Soc Sci Med 1996 43 1601 1610 10.1016/S0277-9536(96)00057-3 8961404 The Telephone Interview for Cognitive Status Brandt J Spencer M Folstein M Neuropsychiatry, Neuropsychology and Behavioral Neurology 1988 1 111 117 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease Morris JC Heyman A Mohs RC Hughes JP van Belle G Fillenbaum G Mellits ED Clark C Neurology 1989 39 1159 1165 2771064 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery Welsh KA Butters N Mohs RC Beekly D Edland S Fillenbaum G Heyman A Neurology 1994 44 609 614 8164812 Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer Stel VS Smit JH Pluijm SMF Visser M Deeg DJH Lips P Journal of Clinical Epidemiology 2004 57 252 258 10.1016/j.jclinepi.2003.07.008 15066685 A way of healthy walking - A guidebook for health promotion practice Stahl T Laukkanen R 2000 http://www.reumaliitto.fi/walking-guide/guide/guide.doc "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician Folstein MF Folstein SE McHugh PR J Psychiatr Res 1975 12 189 198 10.1016/0022-3956(75)90026-6 1202204 Rey A L'examen clinique en psychologie Paris, Presses Universitaires de France 1964 Lezak MD Neuropsychological assessment New York, Oxford University Press, Inc. 3rd 1995 Uiterwijk JM WAIS-III-NL/V Lisse, Swets & Zeitlinger 2001 Cognitive Aging, Attention, and Mild Traumatic Brain Injury Klein M Universiteit Maastricht 1997 95 105 [Abbreviated form of the Informant Questionnaire on cognitive decline in the elderly] de Jonghe JF Schmand B Ooms ME Ribbe MW Tijdschr Gerontol Geriatr 1997 28 224 229 9526793 A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation Jorm AF Psychol Med 1994 24 145 153 8208879 Ware JE Kosinski M Keller SD SF-12: How to score the SF-12 physical and mental health summary scales Boston, MA, The health institute, New England Medical Center Second edition 1995 Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL) Brod M Stewart AL Sands L Walton P Gerontologist 1999 39 25 35 10.1159/000026556 10028768 EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group Health Policy 1990 16 199 208 10.1016/0168-8510(90)90421-9 10109801 Development and validation of a geriatric depression screening scale: a preliminary report Yesavage JA Brink TL Rose TL Lum O Huang V Adey M Leirer VO J Psychiatr Res 1982 17 37 49 10.1016/0022-3956(82)90033-4 7183759 De Groninger fitheidstest voor ouderen: ontwikkeling van een meetinstrument Lemmink K Rijksuniversiteit Groningen 1996

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2318/5/18/prepub